Fisher-Price High Chair Recall Issued After Child Suffers Skull Fracture
About 24,000 Fisher-Price 3-in-1 high chairs have been recalled due to a defective design of the booster seat release, which could cause the seat back to detach or fall backwards, posing a potential fall hazard.
At least one report of problems with the Fisher-Price high chair seat back has been received, involving a young child who suffered a skull fracture in a fall.
The defective Fisher-Price high chairs were sold exclusively at Target stores between December 2008 and March 2009 for about $100.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
The product was marketed as a Fisher-Price “3-in-1 High Chair to Booster,” which contains a removable tray, adjustable seat and converts from a high chair to a booster seat.
The high chair recall applies to units that have the product number P5369 printed on the side of the seat, on a label on the seat pad and on the high chair’s packaging.
There are two main defects in the product. The first involves the booster seat release becoming unlatched while the child is in the chair, causing the seat to fall backwards. The second involves the seatback detaching if it is not fully snapped into place. Both of these problems may cause the child to fall out of the high chair and cause injuries that could be serious.
Parents have been urged to stop using the Fisher-Price high chairs and to contact the manufacturer at (800) 432-5437 to request a free repair kit and instructions. Additional information can also be obtained at www.service.mattel.com.
"*" indicates required fields
More Top Stories
A new report indicates the U.S. Navy is struggling to process tens of thousands of Camp Lejeune water poisoning claims due to a lack of resources.
A group of plaintiffs have filed a motion with the U.S. JPML seeking consolidation of all Bard implanted port lawsuits before one judge for pretrial proceedings.
A Tepezza hearing loss lawsuit accuses the manufacturer of failing to provide adequate warning about the risks of the thyroid eye disease drug.